Exploration of Microbially Derived Natural Compounds against Monkeypox Virus as Viral Core Cysteine Proteinase

Amit Dubey1, Maha M Alawi2,3,4, Thamir A Alandijany2,5

  • 1Computational Chemistry & Drug Discovery Division, Quanta Calculus, Greater Noida 201310, India.

Viruses
|January 21, 2023
PubMed

Insights

Researchers screened 32,552 natural products to find potential monkeypox virus (MPXV) proteinase inhibitors. Gallicynoic Acid F and Vaccinol M showed promising binding and stability, suggesting natural compounds as a therapeutic strategy against MPXV.

Area of Science:

  • Virology
  • Drug Discovery
  • Computational Chemistry

Background:

  • Monkeypox virus (MPXV), an Orthopoxvirus, causes a significant public health concern.
  • MPXV proteinase is crucial for viral replication and represents a key drug target.

Purpose of the Study:

  • To identify potential natural compounds that can inhibit MPXV proteinase.
  • To evaluate the binding affinity and stability of these compounds using computational methods.

Main Methods:

  • High-throughput virtual screening (HTVS) of 32,552 natural products.
  • Molecular docking and 100 ns molecular dynamics simulations.
  • MM/GBSA binding free energy calculations and principal component analysis.

Main Results:

  • Gallicynoic Acid F exhibited the highest binding affinity (-10.56 kcal/mole).
  • Vaccinol M demonstrated stable molecular dynamics with consistent RMSD (2-3 Å).
  • Gallicynoic Acid F and H2-Erythro-Neopterin showed favorable binding free energies (-61.42 and -61.09 kcal/mol, respectively), outperforming the native ligand.

Conclusions:

  • Natural compounds, particularly Gallicynoic Acid F and H2-Erythro-Neopterin, show potential as MPXV proteinase inhibitors.
  • These findings suggest a promising therapeutic avenue for controlling monkeypox disease using natural product-derived drugs.

Related Concept Videos